Lung and pancreatic cancer patients treated with a certain drug who develop a rash live longer, according to a study from the drug's maker.
Patients who got a moderate or severe acne-like rash survived 245 percent longer than those with less severe skin problems, after taking erlontinib, sold as Tarceva by OSI Pharmaceuticals Inc.
Researchers found that in the majority of cases, the more severe the rash, the longer a patient's cancer was held in check, the company said.
source : www.nbc11.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment